Lenvatinib HCC Results Give Sorafenib Cause To REFLECT?
Executive Summary
New comparative data released at ASCO reveal the scope of benefit for Eisai's lenvatinib over close competitor sorafenib in the first-line treatment of unresectable hepatocellular carcinoma. But the Eisai drug may face challenges in carving a position in this setting.